证券简称：*ST 恒立 证券代码：000622 公告编号：2025-44 截至 2025 年 4 月 30 日，你公司未在法定期限内披露过半数董事保证真实、 准确、完整的 2024 年年度报告。根据《关于发布<深圳证券交易所股票上市规则 （2025 年修订）>的通知》第二条、《关于发布<深圳证券交易所股票上市规则 （2024 年修订）>的通知》第三条的规定，你公司触及本所《股票上市规则（2025 年修订）》第 9.3.12 条第七项规定的股票终止上市情形，本所拟决定终止你公司 股票上市交易。 根据本所《股票上市规则（2025 年修订）》《自律监管听证程序细则（2023 年修订）》等相关规定，你公司有权申请听证或者提出书面陈述和申辩。申请听 证的，你公司应当在收到本告知书之日起五个交易日内，以书面形式向本所提出 申请，并载明具体事项及理由。提出陈述和申辩的，你公司应当在收到本告知书 之日起十个交易日内，向本所提交相关书面陈述和申辩。逾期视为放弃听证、陈 述和申辩权利。" 根据《深圳证券交易所股票上市规则》及《关于退市公司进入退市板块挂牌 转让的实施办法》等有关规定，如果深圳证券交易所最终决定公司股票终止上市， ...

证券简称：*ST 恒立 证券代码：000622 公告编号：2025-43 恒立实业发展集团股份有限公司 在立案期间，公司将积极配合中国证券监督管理委员会的调查工作，并严格 按照监管要求履行信息披露义务。 公司董事会郑重提醒广大投资者：公司指定的信息披露媒体为《证券时报》 和巨潮资讯网（www.cninfo.com.cn），公司所有信息均以在上述媒体披露的信息 为准，公司将严格按照有关法律法规的规定和要求履行信息披露义务，及时做好 信息披露工作。请广大投资者理性投资，注意风险。 特此公告 恒立实业发展集团股份有限公司董事会 2025 年 5 月 6 日 关于公司收到立案告知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 恒立实业发展集团股份有限公司（以下简称"公司"）于 2025 年 5 月 6 日收 到中国证券监督管理委员会下发的《立案告知书》（证监立案字 0132025005 号），因公司未按规定期限披露定期报告，根据《中华人民共和国证券法》《中华 人民共和国行政处罚法》等法律法规，中国证券监督管理委员会决定对公司立案。 ...

Summary of Key Points Core Insights - The report highlights various companies undergoing temporary suspensions of trading due to different reasons, including financial disclosures and potential delisting risks. This indicates a volatile market environment where investor confidence may be affected by such events [2][3][4]. Company Specifics - ST Jiuzhi (000989) announced a temporary suspension of trading on May 6, 2025, due to the cancellation of other risk warnings [2]. - In the case of ST Gongzhi (000584), trading was suspended due to a risk warning regarding potential delisting, effective from April 28, 2025 [2]. - ST Hengli (000622) and Tianmao Group (000627) also faced trading suspensions due to their inability to disclose periodic reports within the legal timeframe, effective from May 6, 2025 [2]. - Binhai Energy (000695) is undergoing a trading suspension as it plans to issue shares for asset acquisition and raise matching funds, effective from April 30, 2025 [2]. - Electric Power Investment Energy (002128) is also suspended for similar reasons related to asset acquisition and related party transactions, effective from May 6, 2025 [2]. Industry Context - The report reflects a broader trend in the market where companies are facing increased scrutiny and regulatory challenges, leading to trading suspensions. This could signal potential investment risks in the affected sectors [2][3][4].

Core Viewpoint - Eight A-share listed companies have failed to disclose their annual reports on time, with some actively pursuing delisting, while others face verification issues [1][2][3]. Group 1: Companies with Delayed Annual Reports - The eight companies include Yulong Co., AVIC Industry Finance, Puli Tui, ST Xinchao, Zitian Technology, Jinlitai, Tianmao Group, and *ST Hengli [2][3]. - Among these, Yulong Co., ST Xinchao, AVIC Industry Finance, and Tianmao Group have market capitalizations exceeding 10 billion yuan, with AVIC Industry Finance reaching 30.6 billion yuan [2]. - The remaining four companies have significantly lower valuations, with Jinlitai around 2 billion yuan and the others below 2 billion yuan [2]. Group 2: Reasons for Delayed Reports - Yulong Co. and AVIC Industry Finance are actively pursuing delisting, which prevents them from timely disclosing their 2024 annual reports [3]. - Puli Tui has received a decision from the Shenzhen Stock Exchange regarding the termination of its stock and convertible bonds [3]. - Jinlitai's delay is due to incomplete verification of financial information, while Tianmao Group and ST Xinchao require further information verification [3]. - *ST Hengli cited the need for additional information and delays from the auditing firm as reasons for its report delay [3]. - Zitian Technology failed to complete its audit due to not hiring an annual audit accountant [3]. Group 3: Stock Performance Amid Report Delays - Despite the report delays, ST Xinchao's stock price increased by 38.36% in April, possibly due to competitive takeover offers [4][5]. - In contrast, Tianmao Group and *ST Hengli experienced stock price declines after announcing their report delays, with Tianmao Group's stock hitting the limit down for two consecutive days [4][5]. - The overall market reaction indicates a divergence in investor sentiment, with some companies facing significant operational risks due to their inability to disclose reports on time [5].

Group 1: Corporate Investigations and Issues - China Copper Industry Co., Ltd. director Li Lianbing is under investigation for serious violations of discipline and law [3] - Yong'an Pharmaceutical's actual controller and chairman Chen Yong is under investigation and has been detained [6] - Xianju Pharmaceutical received an administrative penalty of 195 million yuan for price-fixing agreements with competitors [10] Group 2: Corporate Transactions and Financial Warnings - AVIC Capital plans to transfer shares of AVIC Xi'an Aircraft Industry Group and AVIC Avionics to its controlling shareholder for 4.067 billion yuan [7] - Jiangsu Wuzhong's stock will be subject to additional risk warnings due to an audit report with no opinion and non-operational fund occupation by related parties [8] - Tianmao Group and Jinlitai are both unable to disclose their periodic reports on time, leading to stock suspensions [10][11] Group 3: Industry Trends and Changes - Several automotive companies, including Li Auto, Xiaomi, NIO, and Xpeng, are shifting their marketing language from "smart driving" to "assisted driving" [21]

Mergers and Acquisitions - Xingye Yinxin plans to acquire Atlantic Tin Company for approximately 4.54 billion RMB, with a total investment of about 0.98 million AUD at a price of 0.24 AUD per share [1] - Electric Power Investment Energy is undergoing an asset restructuring with its actual controller, State Power Investment Corporation, involving the acquisition of Inner Mongolia Baiyin Hua Coal Power equity [2] - Huibo Yuntong intends to purchase control of Baode Computer System Co., Ltd. through a combination of share issuance and cash payment, with details to be disclosed in a restructuring report [3] Share Buybacks and Increases - Kesi Technology plans to repurchase shares worth between 30 million and 50 million RMB, using self-owned funds for employee stock ownership plans or capital reduction [4] - Fuchuang Precision's major shareholder, Shenyang Advanced Manufacturing Technology Industry Co., Ltd., aims to increase its stake in the company by 1.2 billion to 2.4 billion RMB over the next 12 months [5] Regulatory and Compliance Issues - Yong'an Pharmaceutical's actual controller and chairman, Chen Yong, is under investigation and has been detained, with the company monitoring the situation closely [6] - *ST Gongzhi received a notice of termination of listing due to financial reporting issues, including an audit report with no opinion expressed for the 2024 fiscal year [8] - Xianju Pharmaceutical was fined 195 million RMB for engaging in monopolistic practices related to the pricing of dexamethasone phosphate sodium raw materials [9] - *ST Hengli failed to disclose periodic reports within the legal timeframe, leading to potential termination of its stock listing [10] - Tianmao Group also failed to disclose its periodic reports on time, resulting in stock suspension [11]

证券简称：*ST 恒立 证券代码：000622 公告编号：2025-42 恒立实业发展集团股份有限公司 关于无法在法定期限内披露定期报告致股票可能被终止上市暨 停牌的风险提示公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： ●恒立实业发展集团股份有限公司（以下简称"公司"）因无法在法定期 限内（2025年4月30日）披露2024年年度报告及2025年第一季度报告，根据《深 圳证券交易所股票上市规则》（以下简称"股票上市规则"）的相关规定，公司 股票将于2025年5月6日（星期二）开市起停牌。 ●公司因无法在法定期限内披露2024年年度报告，根据《股票上市规则》 第9.3.12条（七）项"未在法定期限内披露过半数董事保证真实、准确、完整 的年度报告"，公司股票将被深圳证券交易所终止上市。敬请广大投资者谨慎 决策，注意防范风险。 根据《股票上市规则》第9.3.13条，公司股票自2025年5月6日（星期二）开 市起停牌。 根据《股票上市规则》第9.3.14条、第9.3.15条，深圳证券交易所自公司股 票停牌之日起五个交易日内，向公司发出拟终止公司股票 ...

证券简称：*ST 恒立 证券代码：000622 公告编号：2025-41 恒立实业发展集团股份有限公司 一、无法在法定期限内披露报告的原因 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 关于无法在预约日期及预计无法在法定期限内披露定期报告的 深圳旭泰会计师事务所（普通合伙）（以下简称："旭泰会所"）对公司 2024 年年度报告审计过程中，未按照双方签订的《审计业务约定书》及《总体 审计策略》规定的时间、流程以及法定程序开展审计工作，公司于 2025 年 4 月 29 日下午 3 点后才收到旭泰会所出具的正式审计报告及其他相关专项报告。 风险提示公告 特别提示： ●恒立实业发展集团股份有限公司（以下简称"公司"）原定于2025年4月 30日披露2024年年度报告和2025年第一季度报告。因定期报告涉及的部分信息需 要进一步补充提供，公司无法在2025年4月30日披露2024年年度报告和2025年第 一季度报告，也可能无法在法定期限内（2025年4月30日）披露上述定期报告。 ●公司因无法在法定期限内披露 2024 年年度报告和 2025 年第一季度报告， 根据 ...

证券简称：*ST 恒立 证券代码：000622 公告编号：2025-40 恒立实业发展集团股份有限公司 关于公司股票交易异常波动及公司股票可能被终止上市的 风险提示公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 重要风险提示 ●恒立实业发展集团股份有限公司（以下简称"本公司"、"公司"或"恒 立实业"，证券简称：*ST恒立，证券代码：000622）股票连续三个交易日（2025 年4月24日、4月25日、4月28日）收盘价格跌幅偏离值累计达到12％以上，根据 《深圳证券交易所交易规则》的有关规定，公司股票交易属于异常波动情形。 ●公司存在2024年营业收入低于3亿元而被终止上市的风险，公司2024年度 财务会计报告和内部控制报告存在被出具非标准审计意见的风险，公司股票存 在2024年年度报告披露后被终止上市的风险。截至本公告日，公司已多次披露 《关于公司股票可能被终止上市的风险提示公告》，具体详见公司已披露的相 关公告（公告编号：2025-05、2025-07、2025-15、2025-27、2025-33、2025-38、 2025-39）。敬请广大投资 ...

Group 1 - Several listed companies, including *ST Hengli and Aucma, have postponed the disclosure of their 2024 annual reports and 2025 Q1 reports due to delays in audit and preparation work [1] - *ST Hengli has announced a delay in its report disclosure from April 28, 2025, to April 30, 2025, while Aucma's disclosure has been postponed from April 26, 2025, to April 30, 2025 [1] - Both companies have indicated potential risks, with *ST Hengli facing a possible delisting if its 2024 revenue falls below 300 million yuan, and Aucma correcting its previous profit forecast from a profit to a loss of 45 million to 50 million yuan [1][2] Group 2 - *ST Hengli's performance forecast indicates a revenue of 300 million to 350 million yuan for 2024, with total losses expected to be between 35 million and 45 million yuan [2] - The company has highlighted significant discrepancies with its auditors regarding revenue recognition, which could impact its final revenue figures [3] - Additionally, *ST Hengli is facing multiple lawsuits, resulting in the freezing of some bank accounts, which has negatively affected its operational activities [4] Group 3 - Aucma has unexpectedly revised its profit forecast, now expecting a loss of 45 million to 50 million yuan for 2024, with a further loss of 72 million to 78 million yuan when excluding non-recurring items [5] - The revision is attributed to incomplete audit assessments during the initial forecast, leading to the identification of impairment risks and the need for credit impairment provisions [5] - Aucma's declining performance is linked to insufficient domestic consumer demand and increased competition, alongside challenges faced by its new overseas investments [6]